How to Get Prescribed a GLP-1 Medication: Eligibility and Process Explained

Short answer: getting prescribed a GLP-1 medication generally requires meeting specific BMI or weight-related health criteria, going through a clinical evaluation (often including bloodwork), and — if you're using insurance — clearing a prior authorization process. Whether you go through a telehealth provider or an in-person clinic, the underlying medical requirements are the same.

If you're wondering what it actually takes to get a prescription for Wegovy, Zepbound, or a similar medication, here's the real process — the eligibility rules, what a typical evaluation involves, how insurance factors in, and a realistic timeline from first appointment to first dose.

Who Actually Qualifies

FDA-approved GLP-1 weight-loss medications aren't available to just anyone who wants to lose weight — they're approved for specific criteria:

• A BMI of 30 or higher (classified as obesity), regardless of other health conditions, or
• A BMI of 27 or higher (classified as overweight) plus at least one weight-related health condition, such as high blood pressure, type 2 diabetes, high cholesterol, or obstructive sleep apnea

This is the baseline standard written into the FDA labeling for medications like Wegovy and Zepbound, and it's the eligibility bar that most providers — telehealth or in-person — use as their starting point, since it's what the medications are actually approved for.

Who Shouldn't Take These Medications

Beyond the BMI/comorbidity threshold, there are specific situations where these medications are contraindicated or require extra caution:

• Personal or family history of medullary thyroid carcinoma, or Multiple Endocrine Neoplasia syndrome type 2 — both are hard contraindications due to the boxed warning shared by these medications
• History of pancreatitis — treatment is typically stopped if pancreatitis is suspected during use
• Severe gastrointestinal disease, including severe gastroparesis
• Known allergy to the medication or its ingredients
• For tirzepatide specifically, labeling also flags caution around active suicidal ideation, severe psychiatric illness, and diabetic retinopathy as areas requiring careful evaluation

A thorough intake process — whether telehealth or in-person — should be screening for these factors before prescribing, not just checking a BMI box.

What a Legitimate Evaluation Actually Involves

Regardless of whether you're being evaluated by a telehealth provider or an in-person clinic, a proper clinical evaluation for GLP-1 therapy generally includes:

History and exam:

• A detailed weight history, including prior weight-loss attempts and treatments
• Review of current medications and existing health conditions
• Basic measurements: BMI, and often waist circumference and blood pressure

Bloodwork (commonly ordered):

• Fasting glucose and HbA1c, to assess for diabetes or prediabetes
• A comprehensive metabolic panel, covering liver and kidney function and electrolytes
• A fasting lipid panel (cholesterol and triglycerides)
• Thyroid-stimulating hormone (TSH), particularly if thyroid disease is suspected

Some protocols also check pregnancy status for women of childbearing potential, and in higher-risk situations, may include baseline gallbladder imaging or an eye exam if diabetic retinopathy is a concern.

It's worth knowing that GLP-1 medications aren't controlled substances, and they can legally be prescribed by physicians (MDs, DOs) as well as advanced practice clinicians like nurse practitioners and physician assistants, depending on state scope-of-practice rules. There's no special federal certification required specifically to prescribe these drugs.

Telehealth vs. In-Person: Same Standard, Different Format

A legitimate telehealth GLP-1 program should be applying the same clinical standard as an in-person clinic — documenting your BMI and any relevant health conditions, taking an appropriate history, ordering labs where indicated, and screening for the contraindications above. The delivery format is different; the underlying medical bar shouldn't be.

That said, state and federal telehealth rules do add some structure: prescribers generally need to establish a valid clinician-patient relationship (typically via video, sometimes audio), document informed consent, and follow their state's specific scope-of-practice and prescribing rules. GLP-1 medications aren't classified as controlled substances, but some states have additional rules specifically around telehealth prescribing for high-demand medications, and some Medicaid programs apply BMI and prior-treatment criteria that effectively shape who can access these drugs through telehealth, separate from any direct restriction on the format itself.

One area regulators have specifically flagged: the rise of compounded (non-FDA-approved) GLP-1 products through some telehealth channels, with FDA guidance emphasizing that prescribers should be using FDA-approved products and doses, and taking particular care to avoid dosing errors in remote-care settings. This is worth understanding as its own topic when comparing providers — some prescribe brand-name medication exclusively, others offer compounded alternatives, and the distinction matters for both safety and cost.

Insurance and Prior Authorization

If you're planning to use insurance, this is usually the step that adds the most unpredictability to the timeline.

Most commercial and public insurers require prior authorization before covering a GLP-1 medication for weight management. Common requirements include:

• Meeting the BMI/comorbidity thresholds described above
• Documentation of unsuccessful attempts at lifestyle changes (diet and exercise), often over a 3–6 month period
• In some cases, documentation that you've already tried, or have a contraindication to, older weight-loss medications like phentermine

As an example, one Medicaid prior authorization form for Wegovy and Zepbound requires age criteria, the standard BMI thresholds, documentation of specific comorbidities (diabetes, prediabetes, high cholesterol, high blood pressure, sleep apnea), evidence of behavioral or dietary modification efforts, and in some cases prior use of or contraindication to older weight-loss drugs.

Processing time varies significantly:Medicaid programs often process prior authorizations within 24 to 72 hours, while commercial insurance plans can take anywhere from several days to a couple of weeks, depending on how complete your documentation is and how backed up the reviewer's queue happens to be.

If a prior authorization is denied, your options generally include:

• Appealing with additional documentation supporting medical necessity
• Trying a different medication that has more favorable coverage under your specific plan
• Paying out of pocket, or looking into manufacturer patient-assistance programs, if available

A Realistic Timeline

Putting all of this together, here's roughly what the process looks like from first appointment to first dose:

1. Initial evaluation (telehealth or in-person): history, exam, and labs ordered
2. Lab results and eligibility confirmation: typically 3 to 7 days, depending on lab turnaround
3. Prior authorization submission (if using insurance): processing ranges from 24 hours (Medicaid) to 1–2 weeks (some commercial plans)
4. First dose:many patients in academic obesity clinics start treatment within 2 to 4 weeks of their first consultation, though delays are common if documentation is incomplete, coverage is denied, or there's a pharmacy supply shortage for the specific medication

After that, dose titration itself takes time — both Wegovy and Zepbound start at the lowest dose (0.25 mg weekly for semaglutide, 2.5 mg weekly for tirzepatide) and increase roughly every 4 weeks, meaning it typically takes 16 to 20 weeks of follow-up visits and dose adjustments before reaching a maintenance dose.

What This Means When Comparing Providers

Since eligibility criteria are set by FDA labeling rather than by individual providers, you shouldn't see wildly different medical standards between legitimate providers — what does vary significantly is speed, communication style, whether labs are required or optional, whether the provider prescribes brand-name or compounded medication, and how prior authorization support is handled if you're using insurance. These are the practical differences worth comparing, since the underlying medical bar for who qualifies is largely the same wherever you go.

Frequently Asked Questions

See also: Who Qualifies for GLP-1 Medications? for the full breakdown of contraindications and special-population considerations, and Do You Need Labs Before Starting a GLP-1 Medication? for what baseline bloodwork is recommended and why.

Medical disclaimer: RENVA is not a healthcare provider. This article is informational and educational only. It does not constitute medical advice, diagnosis, or a prescription. Always consult a licensed healthcare professional before making health decisions. Full medical disclaimer →

Find providers worth comparing.

Answer a few preference questions — budget, labs, provider model, and cancellation flexibility. Preference-based and informational only.